nutritional priorities to support glp-1 therapy for obesity and lifestyle supportive care recommendations management of with - based therapies: An expert consensus statement using a modified Delphi approach Why do some people lose

Description

Clinical Monitoring Parameters for Hypertensive GLP-1 Users Patients with high blood pressure starting GLP-1 therapy should establish baseline cardiovascular markers and schedule regular follow-up assessments

Conclusions : The increase in GLP-1 and AGEs reveals hormonal-metabolic dysregulation, indicating a high degree of correlation in the complexity and progression of the disease

Recently, newer forms of these drugs, such as Wegovy (semaglutide), have gained widespread attention as a treatment for obesity and weight-related comorbidities

Key challenges with GLP-1s in 2025 Adherence issues and long-term use Adherence to GLP-1s remains a significant challenge despite their proven efficacy in weight management and type 2 diabetes